Congress expands overdose-reversal options in federal opioid-treatment grants
S. 2336 — Halting the Epidemic of Addiction and Loss Act of 2025 · Filed by John Cornyn (R-TX) · 1 cosponsor · Introduced Jul 17, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Department of Health and Human Services to update its grant programs for opioid treatment and prevention to recognize all FDA-approved overdose reversal drugs—not just naloxone—as eligible interventions. Currently, HHS guidance and regulations for opioid-response grants often name only naloxone; this bill mandates that any FDA-approved reversal agent (such as buprenorphine-based products or other emerging treatments) be treated equally in grant eligibility and funding guidance.
Why we flagged it
The bill's operative mechanism is a mandate to broaden the definition of eligible overdose-reversal medications in federal grant programs. It is a straightforward public-health measure designed to remove a de facto restriction on treatment options and align grant guidance with FDA approvals.
What the text implies
- Pharmaceutical manufacturers of non-naloxone reversal agents (e.g., buprenorphine-based products, newer formulations) may see increased demand and grant-funded procurement if providers and programs shift to alternatives.
- States and Tribes administering opioid-response grants will need to update internal policies and training to reflect the expanded menu of approved agents, creating administrative burden but also operational flexibility.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical manufacturers of FDA-approved opioid overdose reversal agents other than naloxone; healthcare providers and community organizations administering opioid-response grants (expanded trea